Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review
- PMID: 34802085
- PMCID: PMC8882568
- DOI: 10.1007/s10792-021-02058-8
Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review
Abstract
Purpose: To provide an overview of the ocular features of rheumatoid arthritis (RA) and of the ophthalmic adverse drug reactions (ADRs) that may be associated with the administration of antirheumatic drugs.
Methods: A systematic literature search was performed using the PubMed, MEDLINE, and EMBASE databases. In addition, a cohort of 489 RA patients who attended the Authors' departments were examined.
Results: Keratoconjunctivitis sicca, episcleritis, scleritis, peripheral ulcerative keratitis (PUK), and anterior uveitis were diagnosed in 29%, 6%, 5%, 2%, and 10%, respectively, of the mentioned cohort. Ocular ADRs to non-steroidal anti-inflammatory drugs are rarely reported and include subconjunctival hemorrhages and hemorrhagic retinopathy. In patients taking indomethacin, whorl-like corneal deposits and pigmentary retinopathy have been observed. Glucocorticoids are frequently responsible for posterior subcapsular cataracts and open-angle glaucoma. Methotrexate, the prototype of disease-modifying antirheumatic drugs (DMARDs), has been associated with the onset of ischemic optic neuropathy, retinal cotton-wool spots, and orbital non-Hodgkin's lymphoma. Mild cystoid macular edema and punctate keratitis in patients treated with leflunomide have been occasionally reported. The most frequently occurring ADR of hydroxychloroquine is vortex keratopathy, which may progress to "bull's eye" maculopathy. Patients taking tofacitinib, a synthetic DMARD, more frequently suffer herpes zoster virus (HZV) reactivation, including ophthalmic HZ. Tumor necrosis factor inhibitors have been associated with the paradoxical onset or recurrence of uveitis or sarcoidosis, as well as optic neuritis, demyelinating optic neuropathy, chiasmopathy, and oculomotor palsy. Recurrent episodes of PUK, multiple cotton-wool spots, and retinal hemorrhages have occasionally been reported in patients given tocilizumab, that may also be associated with HZV reactivation, possibly involving the eye. Finally, rituximab, an anti-CD20 monoclonal antibody, has rarely been associated with necrotizing scleritis, macular edema, and visual impairment.
Conclusion: The level of evidence for most of the drug reactions described herein is restricted to the "likely" or "possible" rather than to the "certain" category. However, the lack of biomarkers indicative of the potential risk of ocular ADRs hinders their prevention and emphasizes the need for an accurate risk vs. benefit assessment of these therapies for each patient.
Keywords: Causality in adverse drug reactions; Disease-modifying antirheumatic drugs; Non-steroidal anti-inflammatory drugs; Ocular adverse drug reactions; Rheumatoid arthritis; Tumor necrosis factor inhibitors.
© 2021. The Author(s).
Conflict of interest statement
The authors have no financial conflict of interest.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8882568/bin/10792_2021_2058_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8882568/bin/10792_2021_2058_Fig2_HTML.gif)
Similar articles
-
Scleromalacia perforans as an early manifestation of late-onset rheumatoid arthritis: a case-based review.Rheumatol Int. 2024 Jun;44(6):1165-1173. doi: 10.1007/s00296-023-05494-0. Epub 2023 Nov 4. Rheumatol Int. 2024. PMID: 37925382 Review.
-
Clinical Correlates, Outcomes, and Predictors of Inflammatory Ocular Disease Associated with Rheumatoid Arthritis in the Biologic Era.J Rheumatol. 2018 May;45(5):595-603. doi: 10.3899/jrheum.170437. Epub 2018 Feb 15. J Rheumatol. 2018. PMID: 29449499
-
Systemic lupus erythematosus and ocular involvement: an overview.Clin Exp Med. 2018 May;18(2):135-149. doi: 10.1007/s10238-017-0479-9. Epub 2017 Dec 14. Clin Exp Med. 2018. PMID: 29243035 Review.
-
Necrotising Scleritis and Peripheral Ulcerative Keratitis Associated with Rheumatoid Arthritis Treated with Rituximab.Klin Monbl Augenheilkd. 2017 Apr;234(4):567-570. doi: 10.1055/s-0042-121315. Epub 2017 Feb 1. Klin Monbl Augenheilkd. 2017. PMID: 28147401 English.
-
Atypical continuous keratitis in a case of rheumatoid arthritis accompanying severe scleritis.Cornea. 2012 Dec;31(12):1493-6. doi: 10.1097/ICO.0b013e31826218c7. Cornea. 2012. PMID: 23023405
Cited by
-
Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention.Infect Dis Ther. 2024 Jul;13(7):1439-1459. doi: 10.1007/s40121-024-00990-7. Epub 2024 Jun 4. Infect Dis Ther. 2024. PMID: 38834857 Free PMC article. Review.
-
The first presentation of a case of nail-patella syndrome newly diagnosed at the onset of rheumatoid arthritis: a case report.BMC Musculoskelet Disord. 2024 Feb 14;25(1):139. doi: 10.1186/s12891-024-07242-2. BMC Musculoskelet Disord. 2024. PMID: 38355529 Free PMC article.
-
Choroidal, retinal, and optic nerve changes in rheumatoid arthritis and primary sjogren's syndrome patients: comparıson with each other and healthy subjects.Int Ophthalmol. 2024 Feb 7;44(1):24. doi: 10.1007/s10792-024-02970-9. Int Ophthalmol. 2024. PMID: 38324105
-
Pathogenesis of Extraarticular Manifestations in Rheumatoid Arthritis-A Comprehensive Review.Biomedicines. 2023 Apr 24;11(5):1262. doi: 10.3390/biomedicines11051262. Biomedicines. 2023. PMID: 37238933 Free PMC article. Review.
-
Ocular disease as the presenting sign of rheumatoid arthritis - An observational case series.Indian J Ophthalmol. 2023 Apr;71(4):1647-1651. doi: 10.4103/IJO.IJO_2765_22. Indian J Ophthalmol. 2023. PMID: 37026317 Free PMC article.
References
-
- Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–1372. - PubMed
-
- Rossini M, Rossi E, Bernardi D, et al. Prevalence and incidence of rheumatoid arthritis in Italy. Rheumatol Int. 2014;34(5):659–664. - PubMed
-
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials